Log in

Company updateBusiness Today

India pharma shifts to high-value drugs to cut China dependence

Positive+20

GreyOak summary

India's pharmaceutical industry is accelerating a shift toward high-value medicines and advanced manufacturing to reduce reliance on Chinese APIs. Domestic market growth hit 17.1% in September 2026, driven by demand for diabetes and cancer treatments. Government PLI schemes have attracted significant investments, while companies like Jubilant Ingrevia are expanding domestic capabilities.

What it affects

  • HealthcarePositive +20

    Industry shifts to high-value drugs and advanced manufacturing.Rolling sentiment Positive +33

Source

Read the original at Business Today

More news

All news →